Clover Health stock has plummeted by nearly 80% since the early June peaks, as “meme enthusiasm” faded. Should investors buy the dip or stay away from CLOV?
Despite Wall Street being generally bullish on HOOD and seeing sizable upside potential ahead, JPMorgan’s Ken Worthington has different thoughts. Here is the analyst’s bear case.